Dyssomnias Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major dyssomnias markets reached a value of US$ 16.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 19.3 Billion by 2034, exhibiting a growth rate (CAGR) of 1.68% during 2024-2034.
The dyssomnias market has been comprehensively analyzed in IMARC's new report titled "Dyssomnias Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dyssomnias are a category of sleep disorders characterized by disturbances in the quality, amount, or timing of sleep. These illnesses involve difficulties with initiating or maintaining sleep, as well as excessive sleepiness or abnormal sleep behaviors. Dyssomnias can significantly impact a person's ability to function during the day and may result in symptoms such as fatigue, decreased concentration, mood changes, and impaired cognitive performance. In rare cases, individuals suffering from these ailments may also experience alterations in appetite, unexpected weight transformations, itching or crawling sensations in the legs, hallucinations, sleep paralysis, etc. The diagnosis of dyssomnias typically involves a comprehensive evaluation of the clinical features, sleep history, and specific diagnostic tests. Polysomnography is also used in patients to monitor various physiological parameters during sleep, such as brain activity, heart rate, respiratory effort, etc., that might help to confirm the prognosis. The healthcare provider may further recommend actigraphy, which involves wearing a wristwatch-like device that records movement and light exposure over an extended period to provide objective data on sleep-wake patterns and can assist in assessing circadian rhythm disease.
The increasing cases of mental health conditions, such as depression, anxiety, post-traumatic stress disorder, etc., which can disrupt normal sleep patterns, are primarily driving the dyssomnias market. In addition to this, the widespread adoption of certain medications, including serotonin-norepinephrine reuptake inhibitors and antihistamines that can alter the levels of neurotransmitters in the brain, is also creating a positive outlook for the market. Moreover, the inflating utilization of cognitive behavioral therapy, since it addresses dysfunctional thoughts or beliefs in patients by promoting more adaptive thinking patterns, is further bolstering the market growth. Apart from this, the increasing demand for mandibular advancement devices to treat sleep-related problems, like snoring and mild to moderate obstructive sleep apnea is acting as another significant growth-inducing factor. These therapeutic tools help to maintain an open airway by repositioning the jaw during sleep. Additionally, the emerging popularity of biofeedback techniques, owing to their several benefits, such as increased self-awareness, reduced stress, regulated sleep-wake cycles, etc., is expected to drive the dyssomnias market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the dyssomnias market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dyssomnias and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dyssomnias market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dyssomnias market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dyssomnias market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dyssomnias marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the dyssomnias market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dyssomnias market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dyssomnias market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of dyssomnias across the seven major markets?
What is the number of prevalent cases (2018-2034) of dyssomnias by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dyssomnias by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of dyssomnias by type across the seven major markets?
How many patients are diagnosed (2018-2034) with dyssomnias across the seven major markets?
What is the size of the dyssomnias patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dyssomnias?
What will be the growth rate of patients across the seven major markets?
Dyssomnias: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dyssomnias drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dyssomnias market?
What are the key regulatory events related to the dyssomnias market?
What is the structure of clinical trial landscape by status related to the dyssomnias market?
What is the structure of clinical trial landscape by phase related to the dyssomnias market?
What is the structure of clinical trial landscape by route of administration related to the dyssomnias market?
The dyssomnias market has been comprehensively analyzed in IMARC's new report titled "Dyssomnias Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dyssomnias are a category of sleep disorders characterized by disturbances in the quality, amount, or timing of sleep. These illnesses involve difficulties with initiating or maintaining sleep, as well as excessive sleepiness or abnormal sleep behaviors. Dyssomnias can significantly impact a person's ability to function during the day and may result in symptoms such as fatigue, decreased concentration, mood changes, and impaired cognitive performance. In rare cases, individuals suffering from these ailments may also experience alterations in appetite, unexpected weight transformations, itching or crawling sensations in the legs, hallucinations, sleep paralysis, etc. The diagnosis of dyssomnias typically involves a comprehensive evaluation of the clinical features, sleep history, and specific diagnostic tests. Polysomnography is also used in patients to monitor various physiological parameters during sleep, such as brain activity, heart rate, respiratory effort, etc., that might help to confirm the prognosis. The healthcare provider may further recommend actigraphy, which involves wearing a wristwatch-like device that records movement and light exposure over an extended period to provide objective data on sleep-wake patterns and can assist in assessing circadian rhythm disease.
The increasing cases of mental health conditions, such as depression, anxiety, post-traumatic stress disorder, etc., which can disrupt normal sleep patterns, are primarily driving the dyssomnias market. In addition to this, the widespread adoption of certain medications, including serotonin-norepinephrine reuptake inhibitors and antihistamines that can alter the levels of neurotransmitters in the brain, is also creating a positive outlook for the market. Moreover, the inflating utilization of cognitive behavioral therapy, since it addresses dysfunctional thoughts or beliefs in patients by promoting more adaptive thinking patterns, is further bolstering the market growth. Apart from this, the increasing demand for mandibular advancement devices to treat sleep-related problems, like snoring and mild to moderate obstructive sleep apnea is acting as another significant growth-inducing factor. These therapeutic tools help to maintain an open airway by repositioning the jaw during sleep. Additionally, the emerging popularity of biofeedback techniques, owing to their several benefits, such as increased self-awareness, reduced stress, regulated sleep-wake cycles, etc., is expected to drive the dyssomnias market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the dyssomnias market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dyssomnias and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dyssomnias market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dyssomnias market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dyssomnias market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dyssomnias marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the dyssomnias market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dyssomnias market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dyssomnias market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of dyssomnias across the seven major markets?
What is the number of prevalent cases (2018-2034) of dyssomnias by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dyssomnias by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of dyssomnias by type across the seven major markets?
How many patients are diagnosed (2018-2034) with dyssomnias across the seven major markets?
What is the size of the dyssomnias patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dyssomnias?
What will be the growth rate of patients across the seven major markets?
Dyssomnias: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dyssomnias drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dyssomnias market?
What are the key regulatory events related to the dyssomnias market?
What is the structure of clinical trial landscape by status related to the dyssomnias market?
What is the structure of clinical trial landscape by phase related to the dyssomnias market?
What is the structure of clinical trial landscape by route of administration related to the dyssomnias market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DYSSOMNIAS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DYSSOMNIAS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DYSSOMNIAS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 DYSSOMNIAS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DYSSOMNIAS - UNMET NEEDS
10 DYSSOMNIAS - KEY ENDPOINTS OF TREATMENT
11 DYSSOMNIAS - MARKETED PRODUCTS
11.1 List of Dyssomnias Marketed Drugs Across the Top 7 Markets
11.1.1 Dayvigo (Lemborexant) - Eisai
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rozerem (Ramelteon) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sonata (Zaleplon) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Mirapex (Pramipexole) - Boehringer Ingelheim
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DYSSOMNIAS - PIPELINE DRUGS
12.1 List of Dyssomnias Pipeline Drugs Across the Top 7 Markets
12.1.1 TS 142 - Taisho Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TAK 861 - Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SUVN-G3031 - Suven Life Sciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AD109 - Apnimed
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DYSSOMNIAS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DYSSOMNIAS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DYSSOMNIAS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dyssomnias - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Dyssomnias - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Dyssomnias - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Dyssomnias - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Dyssomnias - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dyssomnias - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Dyssomnias - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Dyssomnias - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dyssomnias - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Dyssomnias - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Dyssomnias - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dyssomnias - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Dyssomnias - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Dyssomnias - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dyssomnias - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Dyssomnias - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Dyssomnias - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dyssomnias - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Dyssomnias - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Dyssomnias - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dyssomnias - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Dyssomnias - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Dyssomnias - Access and Reimbursement Overview
16 DYSSOMNIAS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DYSSOMNIAS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DYSSOMNIAS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DYSSOMNIAS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DYSSOMNIAS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DYSSOMNIAS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 DYSSOMNIAS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DYSSOMNIAS - UNMET NEEDS
10 DYSSOMNIAS - KEY ENDPOINTS OF TREATMENT
11 DYSSOMNIAS - MARKETED PRODUCTS
11.1 List of Dyssomnias Marketed Drugs Across the Top 7 Markets
11.1.1 Dayvigo (Lemborexant) - Eisai
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rozerem (Ramelteon) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sonata (Zaleplon) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Mirapex (Pramipexole) - Boehringer Ingelheim
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DYSSOMNIAS - PIPELINE DRUGS
12.1 List of Dyssomnias Pipeline Drugs Across the Top 7 Markets
12.1.1 TS 142 - Taisho Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TAK 861 - Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SUVN-G3031 - Suven Life Sciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AD109 - Apnimed
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DYSSOMNIAS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DYSSOMNIAS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DYSSOMNIAS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dyssomnias - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Dyssomnias - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Dyssomnias - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Dyssomnias - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Dyssomnias - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dyssomnias - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Dyssomnias - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Dyssomnias - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dyssomnias - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Dyssomnias - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Dyssomnias - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dyssomnias - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Dyssomnias - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Dyssomnias - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dyssomnias - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Dyssomnias - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Dyssomnias - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dyssomnias - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Dyssomnias - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Dyssomnias - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dyssomnias - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Dyssomnias - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Dyssomnias - Access and Reimbursement Overview
16 DYSSOMNIAS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DYSSOMNIAS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DYSSOMNIAS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
